Intraperitoneal Chemotherapy without Bevacizumab versus Intravenous Chemotherapy plus Bevacizumab as Frontline Therapy in Advanced Ovarian Cancer

Author:

Ting Wan-Hua1,Wang Hsiao-Feng1,Chen Hui-Hua1,Sun Hsu-Dong1,Wei Ming-Chow1,Lin Ho-Hsiung1,Hsiao Sheng-Mou1

Affiliation:

1. Far Eastern Memorial Hospital

Abstract

Abstract Objectives To compare the clinical outcomes between intravenous carboplatin/paclitaxel chemotherapy plus bevacizumab versus intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab as the frontline treatment in women with advanced ovarian, fallopian tube and primary peritoneal cancer. Methods All consecutive women with stage II~IV cancer treated with either frontline intraperitoneal cisplatin/paclitaxel without bevacizumab (IP group) or intravenous carboplatin/paclitaxel with bevacizumab (IVB group) at a tertiary referral center were reviewed. Results A total of 59 women (IP group, n=44; IVB group, n=15) were reviewed. There was no significant difference in the progression-free survival (median: 33.6 versus 14.8 months, p=0.13). However, overall survival (OS) was significantly higher in the IP group, compared with the IVB group (median: not reached versus 31.7 months, p=0.02; adjusted hazard ratio (HR)=0.35, 95% confidence interval (CI)=0.10 to 1.07, p=0.065). Additional predictors for OS include cancer stage and the number of chemotherapy cycles. Besides, the standard dose of 100 mg/m2 cisplatin was a predictor for OS, compared with other intraperitoneal regimens (adjusted HR=0.14, 95% CI=0.02 to 0.87, p=0.03). Conclusions Intraperitoneal cisplatin/paclitaxel chemotherapy without bevacizumab seems to be better in OS, compared to intravenous carboplatin/paclitaxel chemotherapy with bevacizumab in the frontline treatment of women with advanced ovarian cancer.

Publisher

Research Square Platform LLC

Reference30 articles.

1. National Comprehensive Cancer Network Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. (Version 1.2022) [(accessed on 23 January 2023)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf

2. Colombo N, Sessa C, du Bois A et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019;30:672–705.

3. Real-World Data on Detection of Germline and Somatic Pathogenic/Likely Pathogenic Variants in BRCA1/2 and Other Susceptibility Genes in Ovarian Cancer Patients Using Next Generation Sequencing;Stegel V;Cancers (Basel),2022

4. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer;Alberts DS;N Engl J Med,1996

5. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group;Markman M;J Clin Oncol,2001

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3